Search the Newsreel

Orchestra BioMed (OBIO) Earnings Date and Reports 2026

HC Wainwright Expects Stronger Earnings for Biomea Fusion

Price to earnings forward of Zimmer Biomet Holdings, Inc. – BX:ZIM

The article presents the "Price to earnings forward" value for Zimmer Biomet Holdings, Inc. (BX:ZIM) on TradingView. It appears to be a financial data point for the company, indicating its valuation based on future earnings expectations. The page also includes various navigation and information …

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA) has received a "Moderate Buy" consensus rating from six analysts, with an average 12-month price target of $8.20, significantly higher than its current share price of $1.26. Institutional investors hold a substantial 96.72% of the company, and several firms, including …

Zimmer Biomet Q2 Earnings Call Highlights

Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased …

Zimmer Biomet Holdings, Inc. (ZBH) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Zimmer Biomet Holdings, Inc. (ZBH) stock, including its current price, news, and historical data. It notes a recent downgrade by BTIG due to growth challenges and presents performance metrics against the S&P 500. The article …

BioMarin (BMRN) Is Up 6.3% After Raising 2026 Revenue Guidance And Highlighting Voxzogo Momentum

BioMarin Pharmaceutical Inc. (BMRN.MX) Analyst insights, Price targets and Recommendations

This article provides an overview of recent analyst ratings for BioMarin Pharmaceutical Inc. (BMRN.MX), including upgrades, downgrades, and maintained ratings from various financial institutions. It lists the latest price targets and recommendations from firms like Morgan Stanley, Oppenheimer, and Citigroup, along with the dates …

Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen has downgraded Generate Biomedicines (NASDAQ:GENB) from "Hold" to "Sell," despite a broader analyst consensus of "Moderate Buy." This comes after the company reported a quarterly loss of $0.52 per share, missing estimates, and generated $6.31 million in revenue. Institutional activity includes …

Biomea Fusion, Inc. Stock 12‑Month Price Target Cut to $6.71, Implies 433% Upside

Seven analysts have revised Biomea Fusion, Inc.'s average 12-month price target down to $6.71 from $7, though this still represents a significant potential upside of approximately 433% from the August 5th closing price. The consensus rating for the stock remains a "Buy" among eight …

BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Raised to $89.5, Implies 46% Upside

BioMarin Pharmaceutical Inc.'s average stock price target has been raised to $89.5 from $87.83 by 24 analysts, indicating a potential 46% upside based on the Aug. 6 closing price. The consensus rating from 29 analysts remains "Buy," with 22 Buys, 7 Holds, and no …

Ping An Biomedical (NASDAQ: PASW) switches auditors from WWC to Edston

Ping An Biomedical Co., Ltd. (NASDAQ: PASW) announced a change in its independent auditors, replacing WWC, P.C. with Edston Global PAC. The board resolved not to reappoint WWC on August 5, 2026, and appointed Edston effective August 6, 2026. The company confirmed there were …

Axiom Intelligence Acquisition 1 Ord Shs Class A (AXIN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Biomerica Inc (BMRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Biomerica Inc (BMRA), focusing on future EPS and revenue growth estimates. It includes a snapshot of the company's current stock price, market capitalization, and a peer comparison with other healthcare equipment and supplies companies. The forecast is …

Advanced Biomed Inc (ADVB) Stock News Today

This page provides an overview of Advanced Biomed Inc (ADVB) stock, including its current price, market capitalization, P/E ratio, and links to various financial data and analysis tools. The main section indicates that more news will be coming soon for the company.

BioMarin (BMRN) Stock Gains On Higher Outlook Despite Profit Drop

Viomi Technology Co Ltd (VIOT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Viomi Technology Co Ltd (VIOT), noting that no earnings forecast score is currently available, contrasting with the Household Goods industry's average of 7.03. Analysts have set an average price target of $5.00 for VIOT, indicating a significant …

Ping An Biomedical Switches U.S. Auditor to Edston Global PAC

Orchestra Biomed Holdings Inc (OBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Orchestra Biomed Holdings Inc (OBIO) has an earnings forecast score of 8.00, placing it 65th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $12.00, with a range from $10.00 to $20.00, indicating a "Buy" trend based on …

BioMarin Pharmaceutical Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BMRN) 2026-08-07

BioMarin Pharmaceutical's Q2 revenue approached $1 billion, a 20% increase year-over-year, driven by its rare-disease portfolio and the Amicus acquisition. The company raised its full-year guidance for revenue, VOXZOGO revenue, and non-GAAP EPS, projecting significant growth from Amicus therapies and VOXZOGO becoming a $1 …

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

UK's Oxford Biomedica tumbles after annual revenue forecast cut

Imaging Biometrics Ltd. (IBAI.L) stock price, news, quote and history

BioMarin Pharmaceutical Inc (BMRN) Aktuelle Aktien-News

Generate Biomedicines (NasdaqGS:GENB) Stock Forecast & Analyst Predictions

Generate Biomedicines (GENB) is projected to experience a decline in earnings at 10.7% annually, despite an expected 41% annual revenue growth and a 1.6% EPS growth. The company, which is focused on AI-driven drug discovery with a $1.8 billion market cap, faces significant risks …

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) News, Articles, Events & Latest Updates

BioMarin Pharmaceutical Inc. (BMRN) has reported strong Q2 2026 earnings, surpassing estimates in both revenue and profit, driven by significant sales growth and an increased 2026 outlook. The company also announced an early research collaboration with n-Lorem Foundation and the FDA's acceptance of its …

Wilsey Asset Management Inc. Has $36.32 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

Wilsey Asset Management Inc. increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.7% in the second quarter, bringing its total holdings to 421,867 shares valued at $36.32 million. The medical equipment provider recently reported strong Q2 earnings, beating analyst estimates with $2.18 …

Oxford BioMedica shares fall after delays impact revenue expectations

Notícias das Ações da BioMarin Pharmaceutical Inc (BMRN)

Citizens JMP Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $7

Citizens JMP has reiterated its Buy rating on Biomea Fusion (BMEA.US) but has adjusted its price target downwards to $7. This indicates a continued positive outlook on the company despite the revised valuation.

Hariom Pipe Industries Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

WINNERS & LOSERS: Goodwin jumps; Oxford BioMedica trims revenue view

Axiom Intelligence Acquisition 1 Ord Shs Class A (AXIN) Stock News Today

Biomea Fusion Inc (BMEA) Stock News Today

Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Inc. has released its financial results for the second quarter of 2026 and provided a business update. This report details the company's financial performance and outlines recent developments and strategic initiatives.

Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary

Generate Biomedicines, Inc. reported Q2 2026 results with revenue of $6.3M, a 37.7% decline year-over-year, and a net loss of $67.3M, or diluted EPS of $(0.52). The company saw reduced collaboration revenue as partner obligations neared completion but advanced several clinical programs including GB-0895 …